¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"focal proliferative glomerulonephritis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic glomerulonephritis
    ¸¸¼ºÅ丮ÄáÆÏ¿°, ¸¸¼º»ç±¸Ã¼½Å¿°
  • glomerulonephritis
    Å丮ÄáÆÏ¿°, »ç±¸Ã¼½Å¿°
  • idiopathic crescentic glomerulonephritis
    Ư¹ßÃʽ´ÞÅ丮ÄáÆÏ¿°, Ư¹ßÃʽ´޻籸ü½Å¿°
  • intercapillary glomerulonephritis
    ¸ð¼¼°ü»çÀÌÅ丮ÄáÆÏ¿°, ¸ð¼¼°ü°£»ç±¸Ã¼½Å¿°
  • membranoproliferative glomerulonephritis
    ¸·Áõ½ÄÅ丮ÄáÆÏ¿°, ¸·Áõ½Ä»ç±¸Ã¼½Å¿°
  • membranous glomerulonephritis
    ¸·Å丮ÄáÆÏ¿°, ¸·»ç±¸Ã¼½Å¿°
  • mesangiocapillary glomerulonephritis
    Ç÷°ü»çÀÌÁú¸ð¼¼°üÅ丮ÄáÆÏ¿°, »ç±¸Ã¼Ç÷°ü°£Áú¸ð¼¼°ü»ç±¸Ã¼½Å¿°
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º»êÀçÅ丮ÄáÆÏ¿°, ¾Æ±Þ¼º¹ü¹ß»ç±¸Ã¼½Å¿°
  • focal
    1. ±¹¼Ò-, ÃÊÁ¡- 2. º´ÅÍ-
  • focal convulsive seizure
    ÃÊÁ¡°æ·Ã¹ßÀÛ
  • focal dermal hypoplasia
    ±¹¼ÒÁøÇÇÇü¼ºÀúÇÏÁõ
  • focal distance
    ÃÊÁ¡°Å¸®
  • focal epilepsy
    ÃÊÁ¡°£Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • crescentric glomerulonephritis
    Ãʽ´ÞÅ丮ÄáÆÏ¿°, Ãʽ´޻籸ü½Å¿°
  • glomerulonephritis
    Å丮ÄáÆÏ¿°, »ç±¸Ã¼½Å¿°
  • intercapillary glomerulonephritis
    ¸ð¼¼°üÅ丮ÄáÆÏ¿°, ¸ð¼¼°ü°£»ç±¸Ã¼½Å¿°
  • membranoproliferative glomerulonephritis
    ¸·Áõ½ÄÅ丮ÄáÆÏ¿°, ¸·Áõ½Ä»ç±¸Ã¼½Å¿°
  • membranous glomerulonephritis
    ¸·Å丮ÄáÆÏ¿°, ¸·»ç±¸Ã¼½Å¿°
  • mesangiocapillary glomerulonephritis
    »çÀÌÁú¸ð¼¼°üÅ丮ÄáÆÏ¿°, »ç±¸Ã¼°£Áú¸ð¼¼°ü»ç±¸Ã¼½Å¿°
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º»êÀçÅ丮ÄáÆÏ¿°, ¾Æ±Þ¼º¹ü¹ß»ç±¸Ã¼½Å¿°
  • focal distance
    ÃÊÁ¡°Å¸®
  • principal focal distance
    ÁÖÃÊÁ¡°Å¸®
  • focal epilepsy
    ¿îµ¿ÁßÃß¼Õ»ó°£Áú
  • focal
    ±¹¼Ò-, ÃÊÁ¡-, º´ÅÍ-
  • focal hyperkeratosis
    ±¹¼Ò°¢È­°ú´ÙÁõ
  • focal infection
    ±¹¼Ò°¨¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute glomerulonephritis
    ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú).
  • glomerulonephritis
    »ç±¸Ã¼¼º ½Å¿°
  • glomerulonephritis
    »ç±¸Ã¼½Å¿°.
  • glomerulonephritis
    »ç±¸Ã¼½Å¿°.(ÞêϹô÷ãìæú)
  • glomerulonephritis
    »ç±¸Ã¼½Å¿°
  • glomerulonephritis,membranoproliferative
    ¸·Áõ½Ä¼º
  • glomerulonephritis,membranous
    ¸·¼º
  • rapidly progressive (crescentic) glomerulonephritis
    ±Þ¼ÓÁøÇ༺»ç±¸Ã¼½Å¿°(ÐááÜòäú¼àõÞêϹô÷ãìæú)
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇ༺ »ç±¸Ã¼½Å¿°.
  • PVR=>proliferative vitreoretinopathy
    Áõ½ÄÀ¯¸®Ã¼¸Á¸·º´Áõ
  • proliferative arthritis =rheumatoid a.
    Áõ½Ä¼º °üÀý¿° ·ù¸¶Æ¼½º¼º °ü Àý¿° .
  • proliferative arthritis =rheumatoid a.
    Áõ½Ä¼º °üÀý¿°(ñòãÖàõ Î¼ï½æú), ·ù¸¶Æ¼½º¼º °üÀý¿°(¡­Î¼ï½æú)
  • proliferative diabetic retinopathy
    Áõ½Ä´ç´¢¸Á¸·º´Áõ(ñòãÖÓØèñØÑدܻñø).
  • proliferative diabetic retinopathy
    Áõ½Ä¼º ´ç´¢¼º ¸Á¸·º´Áõ(ñòãÖàõ ÓØèñàõ ØÑدܻñø)
  • proliferative endophlebitis
    Áõ½Ä¼º Á¤¸Æ³»¸·¿°(ñòãÖàõ ð¡ØæÒ®Ø¯æú)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • proliferative inflammation
    Áõ½Ä¼º ¿°(ñòãÖàõ æú)
  • proliferative phase
    Áõ½Ä±â
  • proliferative retinopathy
    Áõ½Ä¸Á¸·º´Áõ
  • proliferative stage
    Áõ½Ä±â.
  • proliferative state
    Áõ½Ä»óÅÂ
  • proliferative vitreoretinopathy
    Áõ½ÄÀ¯¸®Ã¼¸Á¸·º´Áõ
  • acute glomerulonephritis
    ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú).
  • acute glomerulonephritis
    ±Þ¼º»ç±¸Ã¼½Å¿°
  • crescentric glomerulonephritis
  • glomerulonephritis
    »ç±¸Ã¼½Å¿°
  • glomerulonephritis
    »ç±¸Ã¼½Å¿°.
  • glomerulonephritis
    »ç±¸Ã¼½Å¿°.(ÞêϹô÷ãìæú)
  • glomerulonephritis
    »ç±¸Ã¼¼º ½Å¿°
  • glomerulonephritis,membranoproliferative
    ¸·Áõ½Ä¼º
  • glomerulonephritis,membranous
    ¸·¼º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ExPGN extracapillary proliferative glomerulonephritis
MesPGN mesangial proliferative glomerulonephritis
MSPGN mesangial proliferative glomerulonephritis
PGN proliferative glomerulonephritis
FGN fibrinogen; focal glomerulonephritis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FNH Focal Nodular Hyperplasia
FSGS Focal Segmental Glomerulosclerosis
FA focal adhesion
FSGS Focal and segmental glomerulosclerosis
FCD Focal cortical dysplasia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • focal epithelial
    ±¹¼Ò¼º »óÇÇ
  • focal infection
    ÃÊÁ¡ °¨¿°
  • focal length
    ÃÊÁ¡ °Å¸®
    Áý±¤ ·»Áî·ÎºÎÅÍ ÃÖ´ë ÃÊÁ¡ À§Ä¡±îÁöÀÇ °Å¸®.
  • focal myelitis
    ¼Ò»ó ô¼ö¿°
  • focal nodular hyperplasia
    ÃÊÁ¡¼º °áÀý¼º °úÁõ½Ä
    À§ Á¾¾çÀ¸·Î ºÐ·ùµÇ´Â °£ÀÇ °áÀý¼º º´º¯ÀÇ ÇÑ À¯ÇüÀ¸·Î¼­ °ú¿ÀÁ¾¼º ¹ßÀ° °á¼Õ¿¡ ±âÀÎÇÑ ´ÜÀÏ Á¾±«¼º º´º¯À¸·Î ÇØ¼®µÇ°í ÀÖ´Ù. ÀÌ´Â ÁÖ·Î ÇǸ·ÇÏ¿¡ Àß »ý±â°í Å©±â´Â ¼ö cm ³»¿ÜÀÌ¸ç ¾ãÀº ÆÐ¸·¿¡ ÀÇÇÏ¿© ÁÖº¯ °£ Á¶Á÷À¸·ÎºÎÅÍ Àß ±¸ºÐµÈ´Ù. Àý´Ü¸é¿¡¼­ Á¾±«ÀÇ °¡¿îµ¥¿¡ º° ¸ð¾çÀÇ ¹ÝÈç
  • focal oral mucitis
    ±¹¼Ò¼º ±¸°­ Á¡¾×Áõ
  • focal plane
    ÃÊÁ¡ ´Ü¸é
  • focal point
    ÃÊÁ¡
    ºûÀÌ Áý±¤ ·»Á ÅëÇØ Áö³ª°¥ ¶§ ±¤¼ÓÀÌ ÃÖ´ëÇÑ ³óÃàµÈ À§Ä¡.
  • focal seizure
    ±¹¼Ò °£Áú
  • focal spot
    ÃÐÁ¡
  • focal trough
    »óÃþ
  • posterior focal point
    ÈÄ ÃÊÁ¡
  • progressive focal neurologic disturbance
    ÁøÇ༺ ±¹¼ÒÀû ½Å°æÇÐÀû Àå¾Ö
  • tumor like focal thickening
    Á¾¾ç °°Àº º´¼Ò ºñ´ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
proliferative retinopathy <ophthalmology, pathology> A disease of the small blood vessels of the retina of the eye.
See: diabetic retinopathy.
Origin: Gr. Pathos = disease
(09 Oct 1997)
acute crescentic glomerulonephritis <nephrology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
acute glomerulonephritis <nephrology> A disease of the kidneys that results in inflammation of the glomerulus (the portion of the kidney that filters the blood).
Conditions which may cause glomerulonephritis include post-streptococcal disease (strep throat), lupus, syphilis, bacterial endocarditis, membranoproliferative glomerulonephritis, sepsis, vasculitis, Goodpasture's syndrome, typhoid fever, Henoch-Schonlein purpura, hepatitis or a viral infection (for example mumps, measles, mononucleosis).
(27 Sep 1997)
acute haemorrhagic glomerulonephritis <nephrology> A disease of the kidneys that results in inflammation of the glomerulus (the portion of the kidney that filters the blood).
Conditions which may cause glomerulonephritis include post-streptococcal disease (strep throat), lupus, syphilis, bacterial endocarditis, membranoproliferative glomerulonephritis, sepsis, vasculitis, Goodpasture's syndrome, typhoid fever, Henoch-Schonlein purpura, hepatitis or a viral infection (for example mumps, measles, mononucleosis).
(27 Sep 1997)
acute post-streptococcal glomerulonephritis <nephrology> A disease of the kidneys that results in inflammation of the glomerulus (the portion of the kidney that filters the blood).
Conditions which may cause glomerulonephritis include post-streptococcal disease (strep throat), lupus, syphilis, bacterial endocarditis, membranoproliferative glomerulonephritis, sepsis, vasculitis, Goodpasture's syndrome, typhoid fever, Henoch-Schonlein purpura, hepatitis or a viral infection (for example mumps, measles, mononucleosis).
(27 Sep 1997)
anti-basement membrane glomerulonephritis Glomerulonephritis resulting from anti-basement membrane antibodies, characterised by smooth linear deposits of IgG and C3 along glomerular capillary walls; includes rapidly progressive glomerulonephritis and glomerulonephritis in Goodpasture's syndrome.
(05 Mar 2000)
rapidly progressive glomerulonephritis <nephrology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
glomerulonephritis <nephrology> A variety of nephritis characterised by inflammation of the capillary loops in the glomeruli of the kidney. It occurs in acute, subacute and chronic forms and may be secondary to haemolytic streptococcal infection. Evidence also supports possible immune or autoimmune mechanisms.
(18 Nov 1997)
glomerulonephritis, IgA Chronic form of glomerulonephritis characterised by recurring haematuria with only slight proteinuria and by deposits of IgA immunoglobulin in the mesangial areas of the renal glomeruli. It usually occurs in young males.
(12 Dec 1998)
glomerulonephritis, membranoproliferative Chronic glomerulonephritis characterised histologically by proliferation of mesangial cells, increase in the mesangial matrix, and a thickening of the glomerular capillary walls. The wall thickening is sometimes said to be a result of the interposition of mesangial cytoplasm or matrix between the basement membrane and the endothelium of the capillary wall. It is often divided into types I and II, and sometimes III. Pathogenesis is not well understood, but some types are thought to involve the immune system, with the complement system, in particular, being implicated.
(12 Dec 1998)
glomerulonephritis, membranous A disease of the glomerulus manifested clinically by proteinuria, and sometimes by other features of the nephrotic syndrome. It is histologically characterised by deposits in the glomerular capillary wall between the epithelial cell and the basement membrane and a thickening of the membrane. Also characteristic are outward projections of the membrane between the epithelial deposits in the form of "spikes". There is some agreement that the deposits are antigen-antibody complexes.
(12 Dec 1998)
membranoproliferative glomerulonephritis <pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
Acronym: MPGN
(26 Mar 1998)
membranous glomerulonephritis <pathology> A kidney disease that occurs due to inflammation of the kidney glomerulus and its basement membrane.
The exact cause is unknown but it appears to be related to the deposition of immune complexes in the basement membrane leading to thickening of the capillary walls. This disorder is a common cause of nephrotic syndrome an is usually how the disease manifests.
Risk factors include primary renal disease, malaria, hepatitis B, lupus, syphilis, cancers and non-Hodgkin's lymphomas. Risks also include exposure to some medications such as gold compounds and penicillamine. Mercury, trimethadione and some skin-lightening creams have also been implicated.
Treatment includes systemic corticosteroids and immunosuppressive agents.
(26 Mar 1998)
mesangiocapillary glomerulonephritis <nephrology, pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
(27 Sep 1997)
chronic glomerulonephritis Glomerulonephritis that presents with persisting proteinuria, chronic renal failure, and hypertension, of insidious onset or as a late sequel of acute glomerulonephritis; the kidneys are symmetrically contracted and granular, with scarring and loss of glomeruli and the presence of tubular atrophy and interstitial fibrosis.
Synonym: chronic nephritis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á